<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="126074">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01912274</url>
  </required_header>
  <id_info>
    <org_study_id>MEI-004</org_study_id>
    <nct_id>NCT01912274</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Pracinostat With Azacitadine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)</brief_title>
  <official_title>A Phase II Open-Label, Single-arm, Two-Stage, Multicenter Trial of Pracinostat in Combination With Azacitidine in Elderly (Age 65 Years or Older) Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MEI Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MEI Pharma, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and effectiveness of pracinostat when
      combined with azacitadine for patients who are 65 years of age or older and have Acute
      Myelogenous Leukemia (AML)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Estimate efficacy rate</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Estimate the rate of complete response (CR) + CR with incomplete blood count recovery (CRi) + morphologic leukemia free state (MLFS) to the combination of pracinostat and azacitidine.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Estimate the overall response rate (ORR) (CR + CRi + partial response [PR]
+ PR with incomplete blood count recovery [PRi] + MLFS) to pracinostat plus azacitidine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete cytogenetic response</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Estimate the rate of complete cytogenetic response (CRc) to pracinostat plus azacitidine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Estimate the rate of complete cytogenetic response (CRc) + molecular complete remission (CRm) to pracinostat plus azacitidine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Estimate the progression-free survival (PFS) duration after pracinostat plus azacitidine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>6 - 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Estimate the overall survival (OS) duration after pracinostat plus azacitidine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability and AE profile</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Assess the tolerability and adverse event (AE) profile of pracinostat when combined with azacitidine</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Pracinostat with azacitadine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 mg of pracinostat by mouth 3 times a week for 3 weeks followed by 1 week of rest repeated every 28 days 75 mg/m2 azacitadine for the first 7 days of each 28 day cycle, via subcutaneous (SC) injection or intravenous (IV) infusion if SC injections are intolerable</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pracinostat with azacitadine</intervention_name>
    <description>Elderly newly diagnosed patients will all receive the combination of pracinostat with azacitadine</description>
    <arm_group_label>Pracinostat with azacitadine</arm_group_label>
    <other_name>SB939</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects aged ≥65 years.

          -  Voluntary written informed consent before performance of any study related procedure
             not part of normal medical care.

          -  Newly diagnosed de novo, secondary, or treatment-related AML with intermediate or
             unfavorable-risk cytogenetics based on the Southwest Oncology Group (SWOG)
             classifications (Slovak et al, 2000).

          -  One prior cycle of therapy with an approved hypomethylating agent (HMA) such as
             azacitidine or decitabine is allowed for either an antecedent hematologic disorder
             (AHD) or AML. Patients are also eligible if they have received lenolidamide,
             immunosuppressive therapy or low dose chemotherapy for their AHD. Prior hydroxyurea
             is allowed.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.

          -  ≥20% blasts in bone marrow.

          -  Peripheral WBC &lt;30,000/uL.

          -  Adequate organ function as evidenced by:

          -  Total bilirubin 2x upper limit of normal (ULN)

          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT)2.5x ULN

          -  Serum creatinine 2x ULN

          -  QT interval corrected according to Fridericia's formula (QTcF) ≤450 milliseconds (ms)
             for male subjects or ≤470 ms for female subjects on ECG at Screening.

          -  Male subjects who are surgically sterile or willing to use adequate contraceptive
             measures or abstain from heterosexual intercourse during the entire study treatment
             period.

          -  Female subjects who are not of childbearing potential.

          -  Willingness and ability to understand the nature of this study and to comply with the
             study and follow up procedures

        Exclusion Criteria:

          -  Acute promyelocytic leukemia (French-American-British [FAB] M3 classification).

          -  Known AML-associated t(15;17), t(8;21), t(16;16), del(16q), or inv(16) karyotype
             abnormalities.

          -  Presence of a malignant disease within the last 12 months, with the exception of
             adequately treated in-situ carcinomas, basal or squamous cell carcinoma, or
             non-melanomatous skin cancer. Other malignancies will be considered on a case-by-case
             basis.

          -  Life-threatening illnesses other than AML, uncontrolled medical conditions or organ
             system dysfunction that, in the Investigator's opinion, could compromise the
             subject's safety, or put the study outcomes at risk.

          -  Uncontrolled or symptomatic arrhythmias, unstable angina, or any Class 3 or 4 cardiac
             diseases as defined by the New York Heart Association (NYHA) Functional
             Classification.

          -  Clinical evidence of central nervous system (CNS) involvement.

          -  Are candidates for intensive chemotherapy (induction chemotherapy, bone marrow, or
             stem cell transplant) within the next 4 months.

          -  Received more than one prior cycle of HMA, previous bone marrow transplant or other
             intensive chemotherapy regimens for either an AHD or AML.

          -  Received prior radiation therapy for extramedullary disease within 2 weeks of study
             enrollment.

          -  Received prior histone deacetylase (HDAC) inhibitor or deacetylase (DAC) inhibitor is
             not permitted such as Istodax (romidepsin/depsipetide) or valproic acid.

          -  Received hematopoietic growth factors: erythropoietin, granulocyte colony stimulating
             factor (G-CSF), granulocyte macrophage colony stimulating factor (GM-CSF), or
             thrombopoietin receptor agonists within 7 days (14 days for Aranesp) prior to study
             enrollment.

          -  Have been treated with any chemotherapeutic agent within 2 weeks or 5 half-lives of
             the first dose of study drug, whichever is longer.

          -  Are being treated with systemic corticosteroids. Inhaled and topical steroids as well
             as intermittent dexamethasone for nausea or vomiting are permitted.

          -  Known history of human immunodeficiency virus (HIV) or active infection with
             hepatitis C virus (HCV) or hepatitis B virus (HBV).

          -  Uncontrolled active systemic infections.

          -  Gastrointestinal (GI) tract disease, causing the inability to take oral medication,
             malabsorption syndrome, a requirement for IV alimentation, prior surgical procedures
             affecting absorption, or uncontrolled inflammatory GI disease (e.g., Crohn's disease,
             ulcerative colitis).

          -  Any disease(s), psychiatric condition, metabolic dysfunction, or findings from a
             physical examination or clinical laboratory test result that would cause reasonable
             suspicion of a disease or condition, that contraindicates the use of study drugs,
             that may increase the risk associated with study participation, that may affect the
             interpretation of the results, or that would make the subject inappropriate for this
             study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guillermo Garcia-Manero, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vanessa Esquibel</last_name>
    <phone>858-369-7174</phone>
    <email>vesquibel@meipharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Ctr</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pennie Lam</last_name>
      <phone>626-256-4673</phone>
      <phone_ext>63192</phone_ext>
      <email>hilam@coh.org</email>
    </contact>
    <investigator>
      <last_name>Samer Khaled, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bay Area Cancer Research Group</name>
      <address>
        <city>Pleasant Hill</city>
        <state>California</state>
        <zip>94523</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305-5821</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marlene Zuraek</last_name>
      <phone>650-736-4031</phone>
      <email>marlenez@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Bruno Medeiros, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terri Eubanks</last_name>
      <phone>404-778-4994</phone>
      <email>terri.eubanks@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Martha Arrelano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Daunov</last_name>
      <phone>773-834-2119</phone>
      <email>mdaunov@bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Olatoysoi Odenike, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inidana Univ Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bobbie Freye</last_name>
      <phone>317-274-2992</phone>
      <email>fryeba@iupui.edu</email>
    </contact>
    <investigator>
      <last_name>S.Hamid Sayar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jamie Crawley</last_name>
      <phone>507-284-5280</phone>
      <email>crawley.jamie@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Mrinal Patnaik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Medical Research Center</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65807</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pearlena Hamlet</last_name>
      <phone>417-820-9742</phone>
      <email>pearlena.hamlet@mercy.net</email>
    </contact>
    <investigator>
      <last_name>Viran Holden, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198-7680</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rose Hoyt</last_name>
      <phone>402-559-4810</phone>
      <email>rhoyt@unmc.edu</email>
    </contact>
    <investigator>
      <last_name>Lori Maness-Harris, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caitlin Marx</last_name>
      <email>marxc@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Elie Traer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College of South Carolina-Hollings Cancer Ctr</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shanta Salzer</last_name>
      <phone>843-792-1463</phone>
      <email>salzers@musc.edu</email>
    </contact>
    <investigator>
      <last_name>Alice Mims, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Betsy Williams</last_name>
      <phone>713-792-1993</phone>
      <email>betsyw@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Guillermo Garcia-Manero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin-Froedtert Cancer Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hemavathy Sunder Raj</last_name>
      <phone>414-805-8970</phone>
      <email>hsunderraj@mcw.edu</email>
    </contact>
    <investigator>
      <last_name>Ehab Attalah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.meipharma.com</url>
    <description>Sponsor website</description>
  </link>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>May 30, 2014</lastchanged_date>
  <firstreceived_date>July 29, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AML</keyword>
  <keyword>open label</keyword>
  <keyword>nonrandomized</keyword>
  <keyword>single arm</keyword>
  <keyword>elderly patients</keyword>
  <keyword>HMA</keyword>
  <keyword>newly diagnosed</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
